Cajoled by the pandemic and ongoing challenges with clinical trials, including studies’ low rates of technical success, protracted timelines, recruitment and retention failures, as well as ever-increasing pressures to find new revenue streams as patent cliffs draw near, drugmakers now want to see digital investments bearing fruit.
